Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells

Although it has been suggested that smad7 blocks downstream signaling of TGF-β, the role of smad7 in the EGF signaling pathway has not been fully elucidated. We determined the effect of smad7 on EGF-induced MMP-9 expression in SKBR3 breast Cancer cells. The expression of smad7 and MMP-9 was increased by EGF or TGF-β1, respectively, and further increased by EGF and TGF-β1 co-treatment. EGF induced the phosphorylation of EGFR, SMAD3, ERK, and JNK, and MMP-9 expression was decreased by the EGFR Inhibitor, AG1478. In addition, EGF-induced MMP-9 expression was inhibited by UO126 (a MEK1/2 inhibitor) or SIS3 (a SMAD3 inhibitor), but not by SP600125 (a JNK Inhibitor). Interestingly, EGF-induced SMAD3 phosphorylation was completely blocked by smad7 over-expression, but not the phosphorylation of ERK and JNK. EGF- or TGF-β1-induced MMP-9 expression was completely decreased by adenoviral-smad7 (Ad-smad7) over-expression. We also investigated the role of SMAD3 on EGF-induced MMP-9 expression and showed that EGF-induced MMP-9 expression was decreased by SMAD3 siRNA transfection, whereas EGF-induced MMP-9 expression was further increased by SMAD3 over-expression, as expected. This study showed that EGF-induced SMAD3 phosphorylation mediates the induction of MMP-9, whereas smad7 inhibits TGF-β1 as well as the EGF signaling pathway in SKBR3 cells.